Manufacturer of Controlled Substances; Notice of Application, 4298 [E7-1402]

Download as PDF 4298 Federal Register / Vol. 72, No. 19 / Tuesday, January 30, 2007 / Notices DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 17, 2006, Mallinckrodt Inc., 3600 North Second Street, St. Louis, Missouri 63147, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the basic classes of controlled substances listed in schedule I and II: Drug Schedule ycherry on PROD1PC64 with NOTICES Codeine-N-oxide (9053) ............... Difenoxin (9168) ........................... Dihydromorphine (9145) ............... Morphine-N-oxide (9307) .............. Norlevorphanol (9634) .................. Normorphine (9313) ...................... Tetrahydrocannabinols (7370) ...... Nabilone (7379) ............................ Alfentanil (9737) ............................ Amphetamine (1100) .................... Ecgonine (9180) ........................... Codeine (9050) ............................. Dextropropoxyphene, bulk (9273) Dihydrocodeine (9120) ................. Diphenoxylate (9170) .................... Diprenorphine (9058) .................... Etorphine HCL (9059) ................... Fentanyl (9801) ............................. Hydrocodone (9193) ..................... Hydromorphone (9150) ................. Levo-alphacetylmethadol (9648) .. Levorphanol (9220) ....................... Meperidine (9230) ......................... Methadone (9250) ........................ Methadone intermediate (9254) ... Methamphetamine (1105) ............. Methylphenidate (1724) ................ Metopon (9260) ............................ Morphine (9300) ........................... Opium extracts (9610) .................. Opium fluid extract (9620) ............ Opium tincture (9630) ................... Opium, granulated (9640) ............. Opium, powdered (9639) .............. Oxycodone (9143) ........................ Oxymorphone (9652) .................... Noroxymorphone (9668) ............... Phenazocine (9715) ...................... Alfentanil (9737) ............................ Remifentanil (9739) ...................... Sufentanil (9740) .......................... Thebaine (9333) ........................... I I I I I I I II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II II 15:36 Jan 29, 2007 Jkt 211001 Dated: January 23, 2007. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E7–1402 Filed 1–29–07; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF LABOR Office of the Secretary Submission for OMB Review: Comment Request January 24, 2007. The firm plans to manufacture the listed controlled substances for internal use and for sale to other companies. Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). VerDate Aug<31>2005 Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, Washington, DC 20537, Attention: DEA Federal Register Representative/ODL; or any being sent via express mail should be sent to DEA Headquarters, Attention: DEA Federal Register Representative/ ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must be filed no later than April 2, 2007. The Department of Labor (DOL) has submitted the following public information collection request (ICR) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (Pub. L. 104–13, 44 U.S.C. chapter 35). A copy of this ICR, with applicable supporting documentation, may be obtained from RegInfo.gov at http://www.reginfo.gov/ public/do/PRAMain or by contacting Darrin King on 202–693–4129 (this is not a toll-free number) / e-mail: king.darrin@dol.gov. Comments should be sent to Office of Information and Regulatory Affairs, Attn: OMB Desk Officer for the Employee Benefits Security Administration (EBSA), Office of Management and Budget, Room 10235, Washington, DC 20503, Telephone: 202–395–7316 / Fax: 202–395–6974 (these are not toll-free numbers), within 30 days from the date of this publication in the Federal Register. The OMB is particularly interested in comments which: • Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; • Evaluate the accuracy of the agency’s estimate of the burden of the proposed collection of information, PO 00000 Frm 00068 Fmt 4703 Sfmt 4703 including the validity of the methodology and assumptions used; • Enhance the quality, utility, and clarity of the information to be collected; and • Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses. Agency: Employee Benefits Security Administration. Type of Review: Extension without change of currently approved collection. Title: Summary Plan Description Requirements Under ERISA. OMB Number: 1210–0039. Type of Response: Third party disclosure. Affected Public: Private Sector: Business or other for-profit and Not-forprofit institutions. Estimated Number of Respondents: 3,200,000. Estimated Number of Annual Responses: 93,457,000. Estimated Total Burden Hours: 262,000. Estimated Total Annualized capital/ startup costs: $0. Estimated Total Annual Costs (operating/maintaining systems or purchasing services): $257,914,000. Description: Section 104(b)(1) of the Employee Retirement Security Act of 1974 (ERISA) requires the administrator of an employee benefit plan to furnish each plan participant and each beneficiary receiving benefits under the plan a copy of the plan’s summary plan description (SPD) within 90 days after an individual becomes a participant and (in the case of a beneficiary) within 90 days after an individual first receives benefits, or, if later, within 120 days after the plan first becomes subject to Part 2 of Title I of ERISA. Section 104(b)(1) further specifies that an updated SPD must be furnished subsequently every fifth year, integrating all plan amendments made within such five-year period. The information required to be contained in the SPD is set forth in section 102(b) of ERISA. If a plan is amended to make a material modification in its terms or to change the information required to be contained in the SPD (other than a material reduction in covered services or benefits under a group health plan), section 104(b)(1) requires the plan administrator to furnish participants and beneficiaries receiving benefits a summary of the material modifications E:\FR\FM\30JAN1.SGM 30JAN1

Agencies

[Federal Register Volume 72, Number 19 (Tuesday, January 30, 2007)]
[Notices]
[Page 4298]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E7-1402]



[[Page 4298]]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on November 17, 2006, 
Mallinckrodt Inc., 3600 North Second Street, St. Louis, Missouri 63147, 
made application by renewal to the Drug Enforcement Administration 
(DEA) to be registered as a bulk manufacturer of the basic classes of 
controlled substances listed in schedule I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Codeine-N-oxide (9053)......................  I
Difenoxin (9168)............................  I
Dihydromorphine (9145)......................  I
Morphine-N-oxide (9307).....................  I
Norlevorphanol (9634).......................  I
Normorphine (9313)..........................  I
Tetrahydrocannabinols (7370)................  I
Nabilone (7379).............................  II
Alfentanil (9737)...........................  II
Amphetamine (1100)..........................  II
Ecgonine (9180).............................  II
Codeine (9050)..............................  II
Dextropropoxyphene, bulk (9273).............  II
Dihydrocodeine (9120).......................  II
Diphenoxylate (9170)........................  II
Diprenorphine (9058)........................  II
Etorphine HCL (9059)........................  II
Fentanyl (9801).............................  II
Hydrocodone (9193)..........................  II
Hydromorphone (9150)........................  II
Levo-alphacetylmethadol (9648)..............  II
Levorphanol (9220)..........................  II
Meperidine (9230)...........................  II
Methadone (9250)............................  II
Methadone intermediate (9254)...............  II
Methamphetamine (1105)......................  II
Methylphenidate (1724)......................  II
Metopon (9260)..............................  II
Morphine (9300).............................  II
Opium extracts (9610).......................  II
Opium fluid extract (9620)..................  II
Opium tincture (9630).......................  II
Opium, granulated (9640)....................  II
Opium, powdered (9639)......................  II
Oxycodone (9143)............................  II
Oxymorphone (9652)..........................  II
Noroxymorphone (9668).......................  II
Phenazocine (9715)..........................  II
Alfentanil (9737)...........................  II
Remifentanil (9739).........................  II
Sufentanil (9740)...........................  II
Thebaine (9333).............................  II
------------------------------------------------------------------------

    The firm plans to manufacture the listed controlled substances for 
internal use and for sale to other companies.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration pursuant to 21 CFR 
1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Deputy Assistant 
Administrator, Office of Diversion Control, Drug Enforcement 
Administration, Washington, DC 20537, Attention: DEA Federal Register 
Representative/ODL; or any being sent via express mail should be sent 
to DEA Headquarters, Attention: DEA Federal Register Representative/
ODL, 2401 Jefferson-Davis Highway, Alexandria, Virginia 22301; and must 
be filed no later than April 2, 2007.

    Dated: January 23, 2007.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E7-1402 Filed 1-29-07; 8:45 am]
BILLING CODE 4410-09-P